Abstracts Archive - Page 300 of 2607 - ACR Meeting Abstracts

Abstract Number: 1692 • ACR Convergence 2024
Single Cell RNA-seq Identifies Circulating Double-negative-2 B-cell Population Associated with Progressive Scleroderma Interstitial Lung Disease
Trinitee Oliver¹, Kim Taylor², Ye Cao³, Takanori Sasaki⁴, Deepak Rao⁵, Nunzio Bottini⁶, Francesco Boin⁶ and Richard Ainsworth⁶, ¹Cedars-Sinai Medical Center, Hawthorne, CA, ²University of California, San Francisco, CA, ³Brigham and Women's Hospital and Harvard Medical School, Boston, Boston, MA, ⁴Brigham and Women's Hospital and Harvard Medical School, Brookline, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Cedars-Sinai Medical Center, Los Angeles, CA
Background/Purpose: B-cell subsets display aberrant function in systemic sclerosis (SSc) pathogenesis and infiltrate the lungs of SSc patients with interstitial lung disease (ILD). B-cells relevance…
Abstract Number: 0679 • ACR Convergence 2024
Comparing Raynaud’s Phenomenon Measurement Tools: Results of the Optimizing Raynaud Phenomenon Outcome Measures in Systemic Sclerosis (ROSS) Study
Rachel Wallwork¹, Haomin Hu², Ami Shah³, Laura Hummers⁴, John Pauling⁵, Victoria Flower⁶, Bambang Parmanto², Andi Saptono² and Robyn Domsic⁷, ¹Johns Hopkins University, Towson, MD, ²University of Pittsburgh, Pittsburgh, PA, ³Division of Rheumatology, Johns Hopkins University, Ellicott City, MD, ⁴Johns Hopkins University, Division of Rheumatology, Baltimore, MD, Ellicott City, MD, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Raynaud’s phenomenon (RP) is the most common symptom in systemic sclerosis (SSc) and can lead to significant morbidity, including digital ulcers and/or gangrene. Despite…
Abstract Number: 1184 • ACR Convergence 2024
Sustained Clinical Effects After a Single Intra-articular Injection of PCRX-201 for Moderate-to-Severe Osteoarthritis of the Knee
Stanley Cohen¹, Philip G Conaghan², Marc Hochberg³, Alan Kivitz⁴, Nino Joy⁵, Derek Jackson⁵, Masato Nakazawa⁵, Mary DiGiorgi⁵ and Jonathan Slonin⁵, ¹Metroplex Clinical Research Center, dallas, TX, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³University of Maryland School of Medicine, Baltimore, MD, ⁴Altoona Center for Clinical Research, Duncansville, PA, ⁵Pacira BioSciences, Inc., Tampa, FL
Background/Purpose: Osteoarthritis of the knee (OAK) is a common and severe disease. Current treatments provide temporary pain relief, demonstrating unmet need. PCRX-201 is a high…
Abstract Number: 1442 • ACR Convergence 2024
Relationship Between Degenerative Lesions over Time in Axial Spondyloarthritis: 10-year Follow-up of the DESIR Cohort
Laura Pina Vegas¹, Floris van Gaalen², Miranda van Lunteren³, Damien Loeuille⁴, Caroline Morizot⁵, Esther Newsum⁶, Pascal Claudepierre⁷, Alain SARAUX⁸, Antoine Feydy⁹, Monique Reijnierse¹, Desiree van der Heijde¹⁰ and Sofia Ramiro¹¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²LUMC, Leiden, Zuid-Holland, Netherlands, ³Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands, ⁴Phd, Nancy Vandoeuvre, Lorraine, France, ⁵Nancy University hospital, Nancy, France, ⁶Nij Smellinghe, Drachten, Netherlands, ⁷CHU Henri Mondor, AP-HP/EpiDermE, UPEC, Créteil, France, ⁸CHU Brest, Brest, France, ⁹CHU Cochin, AP-HP, Paris, France, ¹⁰Department of Rheumatology, Leiden University Medical Center, Meerssen, Netherlands, ¹¹Leiden University Medical Center, Bunde, Netherlands
Background/Purpose: Spinal degenerative lesions (DLs) are commonly seen/reported in radiographs and MRI in axSpA. However, the relationship between the different DLs over time has not…
Abstract Number: 1707 • ACR Convergence 2024
TRBV9-Targeted Bispecific T Cell-Engaging Antibodies to Reset the Autoreactive T Cell Compartment in Spondyloarthritis and HLA-DQ8 Celiac Disease
Stephanie Glavaris, Alexander Pearlman, Jin Liu, Jiaxin Ge, Yuanxuan Xia, Kyle J. Kaeo, Tolulope Awosika, Colin Gliech, Tushar Nichakawade, Nikita Marcou, Chetan Bettegowda, Drew Pardoll, Kenneth W. Kinzler, Shibin Zhou, Bert Vogelstein, Suman Paul and Maximilian F. Konig, The Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Therapies that indiscriminately deplete all T cells carry a high risk of opportunistic infection, precluding their widespread use in T cell-mediated autoimmune diseases. Targeting…
Abstract Number: 1656 • ACR Convergence 2024
Loss of Nr4a1 Expression Protects Cartilage During Post-traumatic Osteoarthritis
Katherine Escalera-Rivera, Jennifer Jonason and Jennifer Anolik, University of Rochester Medical Center, Rochester, NY
Background/Purpose: Osteoarthritis (OA) is a complex disease involving pathological processes in joint tissues such as the cartilage and synovium. Cartilage is degraded by matrix metalloproteinases…
Abstract Number: 1688 • ACR Convergence 2024
Discovery and Validation of a New Classification of ANA-RMDs That Better Predict Long Term Outcomes Compared to Legacy Diagnoses
Jack Arnold¹, Lucy Carter¹, Yuzaiful Yusof², Zoe Wigston², Daniel Toro Dominguez³, Samuel Relton⁴, Guillermo Barturen⁵, Marta Alarcon-Riquelme⁶ and Edward Vital⁷, and PRECISESADS consortium, ¹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ³Centro Pfizer-Universidad de Granada-Junta de Andalucía de Genómica e Investigación Oncológica (GENYO), Granada, Andalucia, Spain, ⁴Leeds Institute of Data Analytics, University of Leeds, Leeds, UK, Leeds, England, United Kingdom, ⁵Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ⁷Leeds Institute of Rheumatic and Musculoskeletal Medicine, Faculty of Medicine and Health, University of Leeds, Leeds, United Kingdom, Leeds, England, United Kingdom
Background/Purpose: ANA-associated RMDs (ANA-RMDs) include SLE, Sjogren’s, Scleroderma, Myositis, and mixed/undifferentiated CTD. Despite overlapping clinical and immunophenotypic features, there is significant disparity in access to…
Abstract Number: 1703 • ACR Convergence 2024
Single Cell and Spatial Transcriptomics Implicate Vascular Cell Orchestration of Inflammatory Changes After Ultraviolet Light Exposure
Rachael Wasikowski¹, Erin Theisen², Jie An³, Lam C. Tsoi¹, Ksenia Anufrieva⁴, Kevin Wei⁵, Johann Gudjonsson⁶ and Keith Elkon³, ¹Michigan, Dept. of Dermatology, Ann Arbor, MI, ²Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ³University of Washington, Seattle, WA, ⁴BWH, Cambridge, MA, ⁵Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁶University of Michigan, Ann Arbor, MI
Background/Purpose: Skin sensitivity to sunlight affects ~70% of systemic lupus erythematosus (SLE). In addition, ultraviolet radiation (UVR) can stimulate systemic disease flares, but how this…
Abstract Number: 1598 • ACR Convergence 2024
Projecting the Impact of Standard, Reduced-Dose, and Minimal-Dose Glucocorticoid Regimens in the Treatment of ANCA-Associated Vasculitis Using Simulation Modeling
Naomi Patel¹, Aaron Wu¹, Shruthi Srivatsan¹, Eli Miloslavsky², Peter Merkel³, John Stone⁴, Hyon K. Choi⁵, Emily Hyle¹ and Zachary Wallace², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital, Newton, MA, ³University of Pennsylvania, Philadelphia, PA, ⁴Massachusetts General Hospital , Harvard Medical School, Concord, MA, ⁵Massachusetts General Hospital, Lexington, MA
Background/Purpose: Glucocorticoids (GCs) remain a cornerstone of treatment of ANCA-associated vasculitis (AAV) but predispose people to infectious, metabolic, and other toxicities. We projected the long-term…
Abstract Number: 1667 • ACR Convergence 2024
Correlates of Physical Activity (PA) in Persons Undergoing Total Knee Arthroplasty (TKA): Does Pain Matter?
Elena Losina¹, Jamie Collins¹, Clare Safran-Norton¹, Mike Paskewicz¹, Faith Selzer², Sonia Pavlesen³, Kelly Frier¹, Jon Dhani¹, Darya Lee¹, Ella Macdonald³, Alexa Streicher³, Linda Ehrlich-Jones⁴, Neil Segal⁵, Christine Pellegrini⁶, Elizabeth Wellsandt⁷, Rowland Chang⁸ and Jeffrey Katz¹, and KArAT Team, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Amesbury, MA, ³University of Buffalo, Buffalo, NY, ⁴Shirley Ryan Ability Lab, Chicago, IL, ⁵University of Kansas, Kansas City, KS, ⁶University of South Carolina, Columbia, SC, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Low PA in persons with symptomatic knee osteoarthritis (OA) has often been attributed to pain. Evolving data suggest that TKA recipients do not increase…
Abstract Number: 1584 • ACR Convergence 2024
Efficacy of Tofacitinib in the Treatment of Early Diffuse Cutaneous Systemic Sclerosis: A Clinical Study in Bangladesh
Md Zahid Amin¹, Nabil Amin khan², Prof. Md. Abu Shahin², Dr. Md. Ariful Islam², Prof. Md. Nazrul Islam², Prof. Syed Atiqul Haq³, Prof. Minhaj Rahim Choudhury³ and Prof. Mohammad Mostafa Zaman⁴, ¹Central Police Hospital, Dhaka, Dhaka, Bangladesh, ²BSMMU, Dhaka, Dhaka, Bangladesh, ³Department of Rheumatology, BSMMU, Dhaka, Dhaka, Bangladesh, ⁴Department of Public Health and Informatics, BSMMU, Dhaka, Dhaka, Bangladesh
Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease characterized by fibrosis, vascular abnormalities, and immune system dysregulation. Current treatment options are limited, and there…
Abstract Number: 1699 • ACR Convergence 2024
Anakinra in Giant Cell Arteritis: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial
Hubert de Boysson¹, Kim Ly², Loik Geffray³, Thomas Quemeneur⁴, Eric Liozon⁵, Holy Bezanahary⁵, Noemie Le Gouellec⁴, Alexandra Audemard⁶, Samuel Deshayes⁷, Jonathan Boutemy⁸, Gwénola Maigné⁸, Nicolas Martin Silva⁸, Jean-Jacques Parienti⁸ and Achille Aouba⁷, ¹Caen university Hospital, Caen, France, ²CHU Limoges, limo, France, ³CH Lisieux, Lisieux, France, ⁴CH Valenciennes, Valenciennes, France, ⁵CHU Limoges, Limoges, France, ⁶Tours, Tours, France, ⁷Service d'immunologie clinique-médecine interne, CHU de Caen Normandie, Caen, France, ⁸CHU Caen, Caen, France
Background/Purpose: A previous retrospective series reported the efficacy and tolerance of anakinra (ANK) in giant cell arteritis (GCA) and called for further validation in a…
Abstract Number: 1595 • ACR Convergence 2024
Tezepelumab for Relapsing or Refractory Eosinophilic Granulomatosis with Polyangiitis: A European Retrospective Study
Margot Poux¹, Matthieu Groh², Alexandra Nanzerkelly³, Marco Caminati⁴, candice Lacroix⁵, stephanie Habib⁶ and Benjamin Terrier⁷, ¹Université de Paris cité, PARIS 04EME, France, ²Foch, Suresnes, France, ³King's college London, London, ⁴Department of Medicine, Asthma, Allergy and Clinical Immunology Section, University of Verona, Verona, Italy, ⁵Université de Paris cité, Paris, ⁶Service de Pneumologie, Hôpital Cochin, APHP Centre et Université Paris Cité, Paris, France, ⁷Service de Médecine interne, Hôpital Cochin, AP-HP, Paris, Ile-de-France, France
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) is a small vessel vasculitis associated with asthma and blood and tissue eosinophilia. EGPA is often associated with glucocorticoid…
Abstract Number: 1701 • ACR Convergence 2024
STING Pathway Activity in SLE Patient Serum Correlates with NFkB Activation, Autoantibody Levels, and a Unique Cytokine Profile That Drives Disease Activity
Hyun Hee Kim¹, Haochen Jiang², Tatiana Ort³, Gary Sims³ and Richard Hanna⁴, ¹AstraZeneca, Gaithersburg, MD, ²University of Nebraska, Omaha, NE, ³Immunology Biosciences, Research and Early Development, Respiratory and Immunology (R&I), BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁴AstraZeneca, Dickerson, MD
Background/Purpose: Systemic lupus erythematosus (SLE) is a heterogenous systemic autoimmune disease which is associated with innate immune activation, type I IFN, inflammasome and NFkB-related cytokines.…
Abstract Number: 1669 • ACR Convergence 2024
Will Investigators Enroll? A Vignette Study to Gauge Investigator Equipoise in a Trial of Surgery vs. Nonoperative Therapy in Subjects with Meniscal Tear and Persistent Pain Following Physical Therapy
Jeffrey Katz¹, Faith Selzer², Katharine Fox³, Jon Dhani³, Kyna Long³, Andrea Carland⁴, Tiffany Thavison⁴, Leslie Bisson⁴, Morgan Jones³, Katherine Krupa³ and Nomi Weiss-laxer⁵, ¹Brigham and Women's Hospital, Brookline, MA, ²Brigham and Women's Hospital, Amesbury, MA, ³Brigham and Women's Hospital, Boston, MA, ⁴University at Buffalo, Buffalo, NY, ⁵U, Buffalo, NY
Background/Purpose: Clinician investigators may be unwilling to enroll all eligible subjects into randomized controlled trials (RCTs) because they feel certain subjects would benefit more from…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].